Get access

Rituximab in the management of refractory myasthenia gravis

Authors

  • Nazlee Zebardast MS,

    1. Department of Neurology, Yale University School of Medicine, 40 Temple Street, Suite 6C, New Haven, Connecticut 06510, USA
    Search for more papers by this author
  • Huned S. Patwa MD,

    1. Department of Neurology, Yale University School of Medicine, 40 Temple Street, Suite 6C, New Haven, Connecticut 06510, USA
    Search for more papers by this author
  • Steven P. Novella MD,

    1. Department of Neurology, Yale University School of Medicine, 40 Temple Street, Suite 6C, New Haven, Connecticut 06510, USA
    Search for more papers by this author
  • Jonathan M. Goldstein MD

    Corresponding author
    1. Department of Neurology, Yale University School of Medicine, 40 Temple Street, Suite 6C, New Haven, Connecticut 06510, USA
    • Department of Neurology, Yale University School of Medicine, 40 Temple Street, Suite 6C, New Haven, Connecticut 06510, USA
    Search for more papers by this author

Abstract

Myasthenia gravis (MG) is an immune-mediated disorder with a variable response to treatment. In this study, patients with refractory MG who were treated with rituximab were identified. A review of patients referred to the Yale Neuromuscular Clinic was performed. Patients with refractory MG who were treated with rituximab were reviewed for response to treatment. Patients who had muscle-specific kinase (MuSK+) or acetylcholine receptor (AChR+) antibodies were included. Six patients were identified who met the criteria described. All patients tolerated rituximab without side effects and had a reduced need for immunosuppressants and/or improvement in clinical function. Patients with refractory MG appeared to respond to rituximab in this small, retrospective study. This result suggests that a larger, prospective trial is indicated. Muscle Nerve, 2009

Ancillary